Zobrazeno 1 - 5
of 5
pro vyhledávání: '"José M. Prieto-González"'
Autor:
Agustín Sancho-Saldaña, Anna Gil-Sánchez, Cristina González-Mingot, Silvia Peralta, Maria Jose Solana, Pascual Torres, Alba Juanes, Laura Quibus, Emilio Ruiz, Eduardo Sanpedro, Bibiana Quirant-Sánchez, Eva Martínez-Cáceres, Cristina Ramo Tello, Silvia Presas-Rodríguez, Sebatián García Rubio, Beatriz Pardiñas Baron, Lluís Ramió-Torrentà, Javier Sotoca, Inés González-Suárez, Sara Eichau, José M. Prieto-González, Maria Rosario Blasco Quilez, Julia Sabín-Muñoz, Antonio José Sánchez-López, Gloria Llorens Calatayud, Carmen Calles, Ángel Pérez Sempere, Moises Garcés, Olga Carmona, Ester Moral, José Vicente Hervás, Yolanda Blanco, Nuria Sola-Valls, Nieves Tellez Lara, Lucía Forero, Luis Brieva
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 23, p 7243 (2023)
Background: The EMCOVID project conducted a multi-centre cohort study to investigate the impact of COVID-19 on patients with Multiple Sclerosis (pwMS) receiving disease-modifying therapies (DMTs). The study aimed to evaluate the seroprevalence and pe
Externí odkaz:
https://doaj.org/article/113662d141fb4a9699c0808fe945e6ff
Autor:
José E. Meca-Lallana, Bonaventura Casanova, Alfredo Rodríguez-Antigüedad, Sara Eichau, Guillermo Izquierdo, Carmen Durán, Jordi Río, Miguel Ángel Hernández, Carmen Calles, José M. Prieto-González, José Ramón Ara, Dionisio F. Uría, Lucienne Costa-Frossard, Antonio García-Merino, Celia Oreja-Guevara
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
BackgroundEarly identification of the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS) can be challenging for clinicians, as diagnostic criteria for SPMS are primarily based on physical disability and a
Externí odkaz:
https://doaj.org/article/aa9c9b31ac3d4967b3581b1660d1bab5
Autor:
Daniel Pérez-Rodríguez, Maria Aránzazu Penedo, Tania Rivera-Baltanás, Tonatiuh Peña-Centeno, Susanne Burkhardt, Andre Fischer, José M. Prieto-González, José Manuel Olivares, Hugo López-Fernández, Roberto Carlos Agís-Balboa
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 3, p 1891 (2023)
Schizophrenia (SZ) is a serious mental disorder that is typically treated with antipsychotic medication. Treatment-resistant schizophrenia (TRS) is the condition where symptoms remain after pharmacological intervention, resulting in long-lasting func
Externí odkaz:
https://doaj.org/article/7780cbc3f36345db98386e7045e520f0
Autor:
Virginia Meca-Lallana, José M. García Domínguez, Rocío López Ruiz, Jesús Martín-Martínez, Adrián Arés Luque, Miguel A. Hernández Pérez, José M. Prieto González, Lamberto Landete Pascual, Jaume Sastre-Garriga
Publikováno v:
Scientia
Cladribine; Disease-modifying drugs; Relapsing multiple sclerosis Cladribina; Medicaments modificadors de malalties; Esclerosi múltiple recurrent Cladribina; Medicamentos modificadores de enfermedades; Esclerosis múltiple recurrente Cladribine is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::639c7a6d67351fe289afdbbbeb02f8e3
https://link.springer.com/content/pdf/10.1007/s40120-022-00394-0.pdf
https://link.springer.com/content/pdf/10.1007/s40120-022-00394-0.pdf
Autor:
José E. Meca-Lallana, José M. Prieto González, Ana B. Caminero Rodríguez, Javier Olascoaga Urtaza, Ana M. Alonso, Eduardo Durán Ferreras, Raúl Espinosa, Julio Dotor, Mercedes Romera, Adrián Ares Luque, Domingo Pérez Ruiz, Carmen Calles, Miguel A. Hernández, Miguel Hervás García, Amelia Mendoza Rodríguez, Yasmina Berdei Montero, Nieves Téllez, Nicolás Herrera Varó, Javier Sotoca, Silvia Presas-Rodríguez, Luis A. Querol Gutierrez, Mariona Hervás Pujol, Jordi Batlle Nadal, Gisela Martín Ozaeta, Laura Gubieras Lillo, Sergio Martínez Yélamos, Lluís Ramió-Torrentà, Javier Mallada Frechin, Antonio Belenguer Benavides, Francisco Gascón-Giménez, Bonaventura Casanova, Lamberto Landete Pascual, Leticia Berenguer, Laura Navarro, Montserrat Gómez Gutierrez, Carmen Durán, Ana Rodríguez Regal, Elena Álvarez, Daniel A. García-Estévez, Ana M. López Real, Miguel A. Llaneza González, María E. Marzo Sola, José L. Sánchez-Menoyo, Agustín Oterino, Ramón Villaverde González, Tamara Castillo-Triviño, Amaya Álvarez de Arcaya, Cristina Llarena
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 2177-2193 (2023)
Abstract Introduction Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing–remitting multiple sclerosis (RRMS; depending on the local label), based on extensive evidence from clinic
Externí odkaz:
https://doaj.org/article/0d5e12714aa14ddbb6e6eadf49cbbed1